Skip to main content

Remote Job Finders (RJF)

Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks

Eli Lilly first linked up with Gate Bioscience in July 2025 to leverage the biotech’s “Molecular Gate” engine to treat diseases with high unmet need. Monday’s expansion will add one undisclosed target to the existing agreement, with an option for a second.

CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential

CSL will co-develop and co-promote Alentis Therapeutics’ anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune disease characterized by small blood vessel inflammation.

Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand

A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for talent, innovation and regulatory strength.
Scroll to top